Comparative Pharmacology
Head-to-head clinical analysis: AVENTYL versus NORPRAMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVENTYL versus NORPRAMIN.
AVENTYL vs NORPRAMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.
Norpramin (desipramine) is a tricyclic antidepressant (TCA) that primarily inhibits the reuptake of norepinephrine, and to a lesser extent serotonin, at the presynaptic neuronal membrane, thereby increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha1-adrenergic blocking properties.
Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.
25 mg orally three times daily; may increase gradually to 150 mg/day in divided doses. Maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 19-24 hours; requires 4-6 days to reach steady state.
Terminal half-life: 18-34 hours (mean ~27 hours); clinical context: supports once-daily dosing, but steady-state requires 5-7 days.
Renal (30% as unchanged drug and metabolites); biliary/fecal (70% as metabolites)
Primarily renal (70%) as metabolites and unchanged drug; biliary/fecal (30%) as metabolites.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant